Baird Maintains Outperform on bluebird bio, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jack Allen maintains an Outperform rating on bluebird bio (NASDAQ:BLUE) but lowers the price target from $7 to $6.
August 15, 2024 | 10:58 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baird analyst Jack Allen maintains an Outperform rating on bluebird bio but lowers the price target from $7 to $6.
The Outperform rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100